This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ920U2_L.jpg
McMillan would join 3M as the financial chief of its healthcare business, which the U.S. industrial conglomerate plans to spin off into a listed company.
3M expects to complete the planned spinoff, which it disclosed last year, by the end of 2023.
Insulet also reaffirmed its annual forecast for sales of its insulin pumps and total revenue.
The company expects full-year revenue growth of 22% to 25%, compared with its previous forecast of 18% to 22% growth. It sees total sales growth of its insulin delivery devices, Omnipod, to be at 25% to 28%, compared with its previous projection of 21% to 25% rise.
